Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493454 · ClinicalTrials.gov registry record · Phase 2
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00493454: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00493454 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493454, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Primary Objective: * Overall Response Rate (ORR). Secondary Objectives: * The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders. * Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR). * Time to next anticancer therapy (TTNT).
Interventions
- DRUG Rituximab
- DRUG Zevalin
- DRUG ^111 In Ibritumomab Tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493454
The ClinicalTrials.gov registry entry for NCT00493454 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT00493454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493454 about?
NCT00493454 is a clinical study titled "Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas". Primary Objective: * Overall Response Rate (ORR). Secondary Objectives: * The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders. * Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR). * Time to next antican...
What is the current status of trial NCT00493454?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2006-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00493454?
The interventions under investigation include: Rituximab (DRUG), Zevalin (DRUG), ^111 In Ibritumomab Tiuxetan (DRUG).
Who is sponsoring clinical trial NCT00493454?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.